At least 26 compounds are in Phase II or Phase III testing with advanced or metastatic breast cancer as the lead indication. Formulations of already marketed drugs, or compounds where breast cancer is not the lead or one of the lead indications, are not included. Source: BCIQ: BioCentury Online Intelligence

Company

Product

Description

MBC status

Eli Lilly and Co. (NYSE:LLY)

Ramucirumab (IMC-1121B)

Human IgG1 mAb receptor antagonist of VEGF receptor 2 (KDR/Flk-1; VEGFR-2)

Ph III

Nektar Therapeutics (NASDAQ:NKTR)/Sanofi (Euronext:SAN; NYSE:SNY)

Etirinotecan pegol (NKTR-102)

Topoisomerase I (TOP1) inhibitor- polymer conjugate

Ph III

Novartis AG (NYSE:NVS)

BKM120

Oral phosphoinositide 3-kinase (PI3K) inhibitor

Ph III